Retina

PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.

Presenters highlight clinical insights and lessons from recent trial data and surgical experience

Inflammasome Therapeutics announced positive phase 2 results achieved by kamuvudine-8 (K8), its investigational drug, for geographic atrophy (GA) and a good safety signal over the 6-month period of evaluation. The company also reported significantly slower GA progression and a visual acuity advantage.

Initiating aflibercept 8 mg or faricimab as a first-line therapy was associated with longer treatment intervals and superior anatomic outcomes in a real-world analysis of more than 12,000 eyes.

Cynthia Toth, MD, of Duke University, discusses new BabySTEPS research showing that retinal nerve fiber layer and choroidal thickness on OCT correlate with 2-year neurodevelopmental outcomes in preterm infants and what it will take to bring bedside screening into routine NICU care.

The long-term outcomes after primary scleral buckling procedures for rhegmatogenous retinal detachments showed high anatomic success, improved vision, and a good safety profile.

Bedside OCT in preterm infants links retinal thickness to motor, cognition, and autism risk at age 2, hinting at earlier brain screening.

Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.

Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.

Ultra-widefield imaging reveals early retinal risk in pediatric patients.

Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.

The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.

Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.

Utilize oral agents, diet and glucose monitoring systems when acting to preserve vision

New pathways are reshaping the management of retinal disease

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.

Retina cells that sense light falter in Alzheimer’s, potentially derailing sleep and body clocks—pointing to new diagnostic and treatment angles.

StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.

Optical coherence tomography angiography found distinctive microvascular signatures in the retinal layers associated with various stages of decline in cognition.

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.

Meeting founder and co-chair Arshad M. Khanani, MD, MA, FASRS, shares what attendees can expect during this year's program, opening the evening of June 12 and running through June 13 in Las Vegas, Nevada.

Samsung Bioepis launched Opuviz, an aflibercept biosimilar, in Europe for wet AMD, DME, retinal vein occlusion, and myopic CNV.